tiprankstipranks
Trending News
More News >
4DMedical Ltd (AU:4DX)
ASX:4DX
Australian Market
Advertisement

4DMedical Ltd (4DX) AI Stock Analysis

Compare
42 Followers

Top Page

AU:4DX

4DMedical Ltd

(Sydney:4DX)

Rating:44Neutral
Price Target:
AU$0.50
▲(92.31%Upside)
4DMedical Ltd's overall stock score is primarily influenced by strong revenue growth, which is offset by significant operational challenges and negative cash flows. The technical indicators suggest mixed market sentiment with no clear direction, while poor valuation metrics further impact the score negatively.

4DMedical Ltd (4DX) vs. iShares MSCI Australia ETF (EWA)

4DMedical Ltd Business Overview & Revenue Model

Company Description4DMedical Ltd (4DX) is a medical technology company specializing in the development and commercialization of advanced respiratory imaging solutions. The company operates primarily within the healthcare and medical imaging sectors, offering innovative products that enhance the diagnosis and management of respiratory diseases. 4DMedical's core product is the XV Technology, a proprietary four-dimensional lung imaging technology that provides detailed insights into lung function and ventilation, assisting clinicians in delivering more precise and effective patient care.
How the Company Makes Money4DMedical Ltd generates revenue primarily through the commercialization and sale of its proprietary respiratory imaging technology, XV Technology. The company earns money by selling or licensing its imaging software and solutions to healthcare providers, hospitals, and research institutions. Key revenue streams include the sale of imaging systems, software licensing fees, and potentially service and support contracts. Additionally, 4DMedical may engage in strategic partnerships and collaborations with healthcare organizations and technology companies to expand its market presence and drive additional revenue through joint ventures or co-development agreements. The company's earnings are influenced by the adoption rate of its technology in clinical settings, regulatory approvals, and its ability to scale operations to meet increasing demand for advanced respiratory diagnostics.

4DMedical Ltd Financial Statement Overview

Summary
4DMedical Ltd shows significant revenue growth, indicating a promising market position. However, persistent losses, negative cash flows, and negative return on equity highlight serious operational challenges.
Income Statement
35
Negative
4DMedical Ltd has shown significant revenue growth over the past year, from AUD 282,181 to AUD 3,754,256, indicating a strong upward trajectory in sales. However, the company remains unprofitable, with a negative net profit margin due to substantial losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.
Balance Sheet
40
Negative
The company maintains a healthy equity ratio due to a substantial stockholders' equity base, despite a moderate level of total liabilities. The debt-to-equity ratio is low, showing conservative leverage. However, the continuous net losses adversely impact the return on equity, which remains negative.
Cash Flow
30
Negative
4DMedical Ltd faces challenges with negative operating and free cash flow, reflecting difficulties in generating cash from its core business activities. The free cash flow growth is negative, indicating ongoing cash burn. However, financing cash flow remains positive, supporting liquidity needs.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue5.86M3.75M282.18K1.05M216.98K1.23M
Gross Profit5.48M3.52M248.03K280.62K125.13K-8.13M
EBITDA-44.64M-31.86M-33.74M-36.34M-18.04M-15.77M
Net Income-39.54M-35.98M-31.46M-24.59M-21.42M-21.98M
Balance Sheet
Total Assets102.01M120.02M92.92M74.31M92.64M15.82M
Cash, Cash Equivalents and Short-Term Investments15.95M30.61M69.58M51.11M80.88M8.43M
Total Debt4.82M5.12M5.14M6.24M1.69M16.49M
Total Liabilities42.15M49.09M21.46M14.80M9.28M27.63M
Stockholders Equity59.86M70.93M71.46M59.51M83.36M-11.81M
Cash Flow
Free Cash Flow-30.37M-31.17M-23.38M-28.35M-15.25M-8.81M
Operating Cash Flow-30.28M-30.87M-22.65M-25.27M-14.52M-7.65M
Investing Cash Flow-1.52M-40.04M-1.61M-3.50M-580.45K-786.45K
Financing Cash Flow-127.96K31.94M42.73M-995.47K87.55M13.78M

4DMedical Ltd Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.26
Price Trends
50DMA
0.27
Negative
100DMA
0.29
Negative
200DMA
0.40
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
52.44
Neutral
STOCH
75.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:4DX, the sentiment is Neutral. The current price of 0.26 is above the 20-day moving average (MA) of 0.25, below the 50-day MA of 0.27, and below the 200-day MA of 0.40, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.44 is Neutral, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:4DX.

4DMedical Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (47)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
AU$193.22M-4.06%20.36%64.81%
55
Neutral
$115.57M-51.08%10.22%-2.94%
49
Neutral
AU$148.37M-58.61%-74.88%
47
Neutral
AU$44.70M-135.33%-27.58%33.69%
47
Neutral
C$200.31M-3.37-23.14%1.85%20.75%-0.36%
45
Neutral
AU$121.14M-35.20%4.68%-155.42%
44
Neutral
AU$118.71M-52.37%471.29%-4.58%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:4DX
4DMedical Ltd
0.25
-0.28
-52.83%
AU:IPD
Impedimed Limited
0.06
-0.01
-14.93%
AU:CYC
Cyclopharm Limited
1.06
-0.49
-31.61%
AU:MX1
Micro-X Ltd.
0.06
-0.01
-14.29%
AU:ARX
Aroa Biosurgery Ltd
0.59
-0.04
-6.35%
AU:EMV
EMvision Medical Devices Ltd.
1.74
-0.28
-13.86%

4DMedical Ltd Corporate Events

4DMedical Secures Contract Renewal and Advances in Lung Imaging
Jul 18, 2025

4DMedical Limited has renewed a three-year contract with the University of Michigan Medical Center, valued at approximately AUD$155,000, allowing the institution to utilize its comprehensive suite of structural lung analysis products. This renewal underscores the trust and value placed on 4DMedical’s technology by leading US institutions. Additionally, a recent multicenter study published in Respiratory Research highlighted the effectiveness of 4DMedical’s X-ray Velocimetry Lung Ventilation Analysis Software in detecting subtle lung diseases, offering actionable insights for patient care. The company also secured a AUD$1.1 million grant to advance AI lung function analysis, further solidifying its position as a pioneer in pulmonary imaging.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.76 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Issues New Shares Under Incentive Plan
Jul 3, 2025

4DMedical Limited has issued 20,294 fully paid ordinary shares following the exercise of options under its Long Term Incentive Plan. This issuance was conducted without a disclosure to investors, in compliance with the Corporations Act, and a cleansing notice has been lodged with the ASX. The move aligns with regulatory requirements and reflects the company’s ongoing commitment to its incentive plans, potentially impacting its financial structure and stakeholder interests.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Ltd Announces Quotation of New Securities on ASX
Jul 3, 2025

4DMedical Ltd has announced the quotation of 20,294 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to strengthen its market position and incentivize its workforce, potentially impacting its operational dynamics and stakeholder interests positively.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Expands U.S. Presence with Olympus SeleCT™ Screening Launch
Jun 10, 2025

Olympus Corporation has launched a new campaign for SeleCT™ Screening in the United States, utilizing 4DMedical’s lung density analysis technology to identify candidates for the Olympus Spiration™ Valve System. This large-scale deployment of AI-based lung imaging marks a significant commercial expansion for 4DMedical, enhancing its clinical utility in early detection and therapy enablement. The partnership addresses the underdiagnosis of COPD, particularly emphysema, and expands 4DMedical’s presence in interventional respiratory care, offering substantial commercial growth opportunities.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Ltd Announces Quotation of New Securities on ASX
Jun 10, 2025

4DMedical Ltd has announced the quotation of 5,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. This move is part of an employee incentive scheme, indicating the company’s commitment to rewarding its workforce and potentially enhancing employee engagement and retention.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Expands Lung Health Portfolio with Imbio Acquisition
May 30, 2025

4DMedical Limited has issued nearly 15 million shares as part of the earnout consideration for its acquisition of Imbio Inc. This strategic move is expected to strengthen 4DMedical’s position in the healthcare industry, particularly in the field of lung health, by integrating Imbio’s capabilities and expanding its technological offerings.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Ltd Announces Quotation of New Securities on ASX
May 29, 2025

4DMedical Ltd has announced the quotation of 14,964,623 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX, effective May 29, 2025. This move is part of a previously announced transaction and is expected to bolster the company’s market presence and provide additional capital for its ongoing operations and strategic initiatives.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Limited Releases Investor Presentation
May 27, 2025

4DMedical Limited has released an investor presentation providing a general overview of the company’s current activities and operations as of May 27, 2025. The presentation is informational and not intended as a financial product advice or an offer for securities, emphasizing the company’s commitment to transparency while highlighting legal restrictions on distribution, particularly in the United States.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Files FDA Submission for Revolutionary CT:VQ™ Lung Imaging Software
May 26, 2025

4DMedical Limited has filed an FDA 510(k) submission for its CT:VQ™ software, a groundbreaking non-contrast CT-based lung imaging product that assesses both ventilation and perfusion in the lungs. This innovation addresses clinical and logistical challenges associated with traditional nuclear VQ imaging, offering higher resolution and accessibility by leveraging existing CT infrastructure. The company anticipates capturing the entire market of one million annual nuclear VQ scans in the U.S., with potential global market expansion. CT:VQ™ is expected to drive long-term growth in demand for lung assessments, transforming pulmonary care by making comprehensive evaluations more accessible, even in facilities without nuclear medicine capabilities.

The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

4DMedical Secures Major Contract with Intermountain Health for PHA™ Product
May 5, 2025

4DMedical Limited has secured a commercial contract with Intermountain Health, a prominent U.S. health system, for its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product. This contract, facilitated through a strategic partnership with Nuance Communications, marks the first major deployment of the PHA™ algorithm in a large health network, enhancing clinical decision-making and potentially expanding 4DMedical’s market presence. The agreement represents a significant opportunity for revenue growth as it transitions to full commercial terms, with plans to increase usage and expand to other products within the health system.

4DMedical’s Top 20 Investors Hold Majority Stake
May 2, 2025

4DMedical Ltd has released its First 20 Investors Report, detailing the top investors holding significant shares in the company. The report reveals that the top 20 investors collectively hold 51.61% of the company’s issued capital, with CITICORP NOMINEES PTY LIMITED leading at 21.15%. This concentration of ownership among a few key investors could impact the company’s strategic decisions and market influence.

4DMedical Ltd Announces New Securities Quotation on ASX
May 2, 2025

4DMedical Ltd has announced the application for quotation of new securities on the ASX, specifically options expiring on February 28, 2026. This move involves issuing listed options to participants of their recent SPP and placement, potentially enhancing the company’s capital structure and market presence.

4DMedical Successfully Passes All Resolutions at Extraordinary General Meeting
May 1, 2025

4DMedical Limited announced that all resolutions proposed at its Extraordinary General Meeting were successfully passed. This outcome supports the company’s strategic initiatives, including the ratification of share issues and the approval of new options, which are expected to strengthen its financial position and operational capabilities. These developments are likely to enhance 4DMedical’s industry positioning and provide further value to its stakeholders.

4DMedical Reports Strong Revenue Growth and Strategic Advancements in Q3 FY2025
Apr 29, 2025

4DMedical Limited reported a significant increase in operating revenue for the year-to-date FY2025, achieving a 103% rise compared to the previous period, with gross margins of 91.4%. The company is expanding its sales pipeline and has secured key contracts, including a renewal with the Cleveland Clinic and conversions of pilot programs into commercial contracts. A cost reduction program has been implemented, resulting in $6.5 million in annualized savings. The company is preparing for the FDA submission of its CT:VQ™ product, which has attracted interest from major medical centers and industry collaborators. Additionally, 4DMedical has received regulatory clearance for its CT LVAS™ in Canada and has been highlighted by Philips as a solution for improving veteran health outcomes.

4DMedical Ltd Announces Quotation of New Securities on ASX
Apr 24, 2025

4DMedical Ltd has announced the quotation of 131,498 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code 4DX. These securities were issued as part of an employee incentive scheme and are not subject to transfer restrictions, indicating a strategic move to incentivize and retain talent within the company.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025